Cargando…
The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma
BACKGROUND: Pituitary adenoma and meningioma are the most common benign tumors in the central nervous system. Pituitary adenoma associated with meningioma (PAM) is a rare disease and the clinical features and mechanisms of PAM are unclear. METHODS: We summarized the clinical data of 57 PAM patients...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821033/ https://www.ncbi.nlm.nih.gov/pubmed/31665029 http://dx.doi.org/10.1186/s12967-019-2103-0 |
_version_ | 1783464071564099584 |
---|---|
author | Zhu, Haibo Miao, Yazhou Shen, Yutao Guo, Jing Xie, Weiyan Zhao, Sida Dong, Wei Zhang, Yazhuo Li, Chuzhong |
author_facet | Zhu, Haibo Miao, Yazhou Shen, Yutao Guo, Jing Xie, Weiyan Zhao, Sida Dong, Wei Zhang, Yazhuo Li, Chuzhong |
author_sort | Zhu, Haibo |
collection | PubMed |
description | BACKGROUND: Pituitary adenoma and meningioma are the most common benign tumors in the central nervous system. Pituitary adenoma associated with meningioma (PAM) is a rare disease and the clinical features and mechanisms of PAM are unclear. METHODS: We summarized the clinical data of 57 PAM patients and compared with sporadic pituitary adenoma (SPA) and sporadic meningioma (SM). 5 pituitary adenomas of PAM and 5 SPAs were performed ceRNA microarray. qRT-PCR, Western Blot, siMEN1 and rapamycin inhibition experiment were validated for ceRNA microarray. RESULTS: Clinical variable analyses revealed that significant correlations between PAM and female sex as well as older age when compared with SPA and significant correlations between PAM and transitional meningioma as well as older age when compared with SM. Additionally, the characteristics of PAM were significantly different for MEN1 patients. Functional experiments showed lower expression of MEN1 can upregulate mTOR signaling, in accordance with the result of ceRNA microarray. Rapamycin treatment promotes apoptosis in primary pituitary adenoma and meningioma cells of PAM. CONCLUSIONS: MEN1 plays an important role in PAM by upregulating mTOR signaling pathway. Rapamycin represents a potential therapeutic strategy for PAM in the future. |
format | Online Article Text |
id | pubmed-6821033 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68210332019-11-04 The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma Zhu, Haibo Miao, Yazhou Shen, Yutao Guo, Jing Xie, Weiyan Zhao, Sida Dong, Wei Zhang, Yazhuo Li, Chuzhong J Transl Med Research BACKGROUND: Pituitary adenoma and meningioma are the most common benign tumors in the central nervous system. Pituitary adenoma associated with meningioma (PAM) is a rare disease and the clinical features and mechanisms of PAM are unclear. METHODS: We summarized the clinical data of 57 PAM patients and compared with sporadic pituitary adenoma (SPA) and sporadic meningioma (SM). 5 pituitary adenomas of PAM and 5 SPAs were performed ceRNA microarray. qRT-PCR, Western Blot, siMEN1 and rapamycin inhibition experiment were validated for ceRNA microarray. RESULTS: Clinical variable analyses revealed that significant correlations between PAM and female sex as well as older age when compared with SPA and significant correlations between PAM and transitional meningioma as well as older age when compared with SM. Additionally, the characteristics of PAM were significantly different for MEN1 patients. Functional experiments showed lower expression of MEN1 can upregulate mTOR signaling, in accordance with the result of ceRNA microarray. Rapamycin treatment promotes apoptosis in primary pituitary adenoma and meningioma cells of PAM. CONCLUSIONS: MEN1 plays an important role in PAM by upregulating mTOR signaling pathway. Rapamycin represents a potential therapeutic strategy for PAM in the future. BioMed Central 2019-10-29 /pmc/articles/PMC6821033/ /pubmed/31665029 http://dx.doi.org/10.1186/s12967-019-2103-0 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Zhu, Haibo Miao, Yazhou Shen, Yutao Guo, Jing Xie, Weiyan Zhao, Sida Dong, Wei Zhang, Yazhuo Li, Chuzhong The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma |
title | The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma |
title_full | The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma |
title_fullStr | The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma |
title_full_unstemmed | The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma |
title_short | The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma |
title_sort | clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821033/ https://www.ncbi.nlm.nih.gov/pubmed/31665029 http://dx.doi.org/10.1186/s12967-019-2103-0 |
work_keys_str_mv | AT zhuhaibo theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma AT miaoyazhou theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma AT shenyutao theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma AT guojing theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma AT xieweiyan theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma AT zhaosida theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma AT dongwei theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma AT zhangyazhuo theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma AT lichuzhong theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma AT zhuhaibo clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma AT miaoyazhou clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma AT shenyutao clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma AT guojing clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma AT xieweiyan clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma AT zhaosida clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma AT dongwei clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma AT zhangyazhuo clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma AT lichuzhong clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma |